Drug Profile
Livmoniplimab - AbbVie
Alternative Names: ABBV-151; ARGX-115; MHG-8Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Catholic University of Louvain; Ludwig Institute for Cancer Research
- Developer AbbVie
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer
- Phase I Solid tumours
Most Recent Events
- 01 Feb 2024 Abbvie plans a phase II/III LIVIGNO-4 trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) (IV) in April 2024 (NCT06236438)
- 25 Jan 2024 Efficacy, adverse event and pharmacokinetics data from phase I trial in Solid tumours presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 03 Nov 2023 AbbVie plans a phase II/III LIVIGNO-2 trial for Liver cancer (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable, First line therapy) (IV) (NCT06109272)